The present invention relates to a concentrated melatonin solution, wherein melatonin is present in a quantity of 10.0% or higher in a substantially water-free carrier mixture of ethanol and a polyethoxylated derivative. (justia.com)
The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. (justia.com)
The present invention is directed to pharmaceutical solid, oral dosage forms which exhibit a modified release profile. (justia.com)
The present Invention relates to the field of pharmaceutical formulation science, In particular wfth respect to methods of improving solubility and bioavailability of lipophilic compounds. (allindianpatents.com)
The specific formulation technique of the present invention relates to stabilised supersaturated solid solutions of lipophilic drugs, such as steroidal molecules and hormones In general. (allindianpatents.com)
Compositions4
Compositions of the invention may comprise a delayed-release coating disposed over a tight junction agonist and/or tight junction antagonist layer which may be disposed over an inert core. (justia.com)
EP 0474 098 relates to the formulation of solid compositions comprising a hardly soluble drug substance co-precipitated with 3 carrfer comprising a water-soluble excipient (PVP) and a blodegradable excipient (polyactic acid). (allindianpatents.com)
US 6 027 747 relates to the formulation of solid compositions comprising a hardly soluble drug substance together with a carrier (PVP). (allindianpatents.com)
Watanabe T et al relates to the formulation of solid compositions comprising indomethacin and silica. (allindianpatents.com)
Pharmaceutical1
The invention is particularly suitable for once-a-day solid oral pharmaceutical dosage forms in which the active ingredient is memantine, releasing a therapeutically effective amount of the active ingredient over an extended time period. (justia.com)
Carrier2
WO 03/04360 relates to the formulation of solid dispersions comprising a poorly water-soluble drug in combination with a carrier (PVP). (allindianpatents.com)
relates to the formulation of solid dispersions comprising a hardly soluble drug substance together with a carrier (PVP), wherein the the drug substance is present in amorphous form or in crystalline form (Khougaz K et al. (allindianpatents.com)
Oral1
Later, DMF combined with three other fumaric acid esters (FAE) was licensed in Germany as oral therapy for psoriasis (Fumaderm). (med-chemist.com)
Active2
The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. (justia.com)
An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. (lookformedical.com)
Present invention relates3
The present invention relates to compounds that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. (justia.com)
The present invention relates to a remedy and/or a preventive for a chronic disease comprising an EDG (Endothelial differentiation gene)-2 antagonist. (justia.com)
More specifically, the present invention relates to a remedy and/or a preventive for a chronic disease selected from diseases induced by the progress of chronic asthma, glomerular nephritis, obesity, prostate hyperplasia, arteriosclerosis which are induced and made chronic by the sthenia of cell proliferation, rheumatoid, atopic dermatitis, comprising an EDG-2 antagonist. (justia.com)
Alkyl3
5,278,303, 5,605,976 and 5,681,567 report the preparation of PEG carboxylic acids containing little or no starting material (PEG alcohol) by employing a tertiary alkyl haloacetate to prepare a tertiary alkyl ester-fonctionalized PEG, which is then hydrolyzed with acid, preferably trifluoroacetic acid (TFA). (allindianpatents.com)
Accordingly, these tertiary alkyl esters are conventionally cleaved with acid, typically with TFA. (allindianpatents.com)
Lysophosphatidic acid of formula (wherein R is acyl, alkenyl or alkyl) is a lipid which is produced in cell membranes or in blood of living organisms, and it acts as a signal transduction substance and delivers various signals into cells. (justia.com)
Chronic1
The effectiveness of NSAIDs for treating non-cancer chronic pain and cancer-related pain in children and adolescents is not clear. (cloudfront.net)
Presence2
The compounds of the present invention differ in the presence of a pyridazine instead of a pyrimidine and the unexpected finding that they exert an antagonistic effect at the dopamine D2 receptor. (justia.com)
The presence of residual trifluoroacetic acid results in poor product stability, due to degradation of the polymer caused by acid-promoted autoxidation. (allindianpatents.com)